EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

New Inhibitors of β‐1,4‐Galactosyltransferase I Discovered by Virtual Screening

Jaka Kranjc, Tihomir Tomašič iD, Stane Pajk iD, Matjaž Brinc iD, Anja Pišlar iD, Marko Anderluh iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202400896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Jaka Kranjc und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Pharmacy, University of Ljubljana, Faculty of Pharmacy, Aškerčeva cesta 7, SI-1000, Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Galactosyltransferases, Enzyme Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: OpenEye Scientific Software, Slovenian Research Agency, Novartis Pharmaceutical Manufacturing LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Seven different enzymes comprise the galactosyltransferases family, of which β‐1,4‐galactosyltransferase I (β‐1,4‐GALT1) is the major contributor to galactosylation activity in cells. Since abnormalities in galactosylation are associated with many pathophysiological conditions, β‐1,4‐GALT1 is an interesting new target for drug discovery and molecular probe design. There are several known β‐1,4‐GALT1 inhibitors, but most of them suffer from low cell permeability and thus low in vivo activity. In the present work, we describe an in silico screening performed using commercially available virtual compound libraries that led us to the discovery of novel β‐1,4‐GALT1 inhibitors. A virtual screening campaign was performed by docking compound libraries to the binding site of β‐1,4‐GALT1, followed by biological evaluation of selected hits for their β‐1,4‐GALT1 inhibitory activity. The IC 50 values were determined for the best performing inhibitors to obtain new chemotypes of β‐1,4‐GALT1 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GalactosyltransferasesEnzyme InhibitorsHumansMolecular Docking SimulationStructure-Activity RelationshipBinding SitesMolecular StructureDose-Response Relationship, DrugDrug Evaluation, PreclinicalSmall Molecule Libraries

Stichwörter der Autor:innen

Enzyme inhibitorGalactosyltransferaseUDP-Glo assayVirtual screeningβ-1,4-galactosyltransferase I

Substanzen

GalactosyltransferasesEnzyme Inhibitorsbeta-1,4-galactosyltransferase ISmall Molecule Libraries

Autor:innen und Institutionen

  • Institute for Pharmacy, University of Ljubljana, Faculty of Pharmacy, Aškerčeva cesta 7, SI-1000, Ljubljana, Slovenia.
  • Department of Pharmaceutical Chemistry, University of Ljubljana, Faculty of Pharmacy, Aškerčeva cesta 7, SI-1000, Ljubljana, Slovenia.
  • Drug Substance Development, Biologics & Cell and Gene Therapy, Technical Research & Development, Novartis Pharmaceutical Manufacturing LLC, Kolodvorska 27, SI-1234, Mengeš, Slovenia.
  • Department of Pharmaceutical Biology, University of Ljubljana, Faculty of Pharmacy, Aškerčeva cesta 7, SI-1000, Ljubljana, Slovenia.

ORCID-Profile: Tihomir Tomašič, Stane Pajk, Matjaž Brinc, Anja Pišlar, Marko Anderluh

Förderung

  • OpenEye Scientific Software
  • Slovenian Research Agency
  • Novartis Pharmaceutical Manufacturing LLC
  • The Slovenian Research and Innovation Agency

Zitieren

APA

Kranjc, J., Tomašič, T., Pajk, S., Brinc, M., Pišlar, A., & Anderluh, M. (2025). New Inhibitors of β‐1,4‐Galactosyltransferase I Discovered by Virtual Screening. ChemMedChem. https://doi.org/10.1002/cmdc.202400896

Vancouver

Kranjc J, Tomašič T, Pajk S, Brinc M, Pišlar A, Anderluh M. New Inhibitors of β‐1,4‐Galactosyltransferase I Discovered by Virtual Screening. ChemMedChem. 2025. doi:10.1002/cmdc.202400896

BibTeX
@article{Kranjc2025,
  author = {Kranjc, Jaka and Tomašič, Tihomir and Pajk, Stane and Brinc, Matjaž and Pišlar, Anja and Anderluh, Marko},
  title = {New Inhibitors of β‐1,4‐Galactosyltransferase I Discovered by Virtual Screening},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202400896}
}
Kostenlos starten →